Regulus Therapeutics Inc
RGLS7.980USD
+4.610+136.80%
收盤 04/30, 16:00（美東）報價延遲15分鐘
522.69M總市值
虧損本益比TTM
關於 Regulus Therapeutics Inc 公司
Regulus Therapeutics Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發針對 microRNA 的藥物，以治療具有重大未滿足醫療需求的疾病。該公司專注於孤兒腎病，這些疾病涉及 microRNA 遺傳驅動因素，並且存在明顯未滿足的醫療需求。其候選產品 RGLS8429 是一種針對 miR-17 的抗 miR 下一代寡核苷酸，用於治療常染色體顯性多囊腎病 (ADPKD)，目前處於 1b 期臨牀開發階段。除了這個項目之外，該公司還繼續推進和擴展其內部發現渠道，以確定潛在的候選產品。microRNA 是天然存在的核糖核酸 (RNA) 分子，在調節關鍵生物途徑方面發揮着關鍵作用。ADPKD 是常見的人類單基因疾病之一，也是終末期腎病的病因。
公司簡介
公司代碼RGLS
公司名稱Regulus Therapeutics Inc
上市日期Oct 04, 2012
成立日期2007
CEOMr. Joseph P. (Jay) Hagan
員工數量34
證券類型Ordinary Share
年結日Oct 04
公司地址4224 Campus Point Court
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編92121
電話18582026300
網址https://www.regulusrx.com/
公司代碼RGLS
上市日期Oct 04, 2012
成立日期2007
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
Ms. Pascale Witz
Ms. Pascale Witz
Independent Director
Independent Director
4.73K
--
Mr. Joseph P. (Jay) Hagan
Mr. Joseph P. (Jay) Hagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
978.39K
+75.85%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
45.48K
+686.54%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Director
Independent Director
39.06K
--
Mr. Preston S. Klassen, M.D.
Mr. Preston S. Klassen, M.D.
President, Head of Research & Development, Director
President, Head of Research & Development, Director
36.05K
--
Dr. David Baltimore, Ph.D.
Dr. David Baltimore, Ph.D.
Independent Director
Independent Director
22.17K
+766.31%
收入明細
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 2月23日 週日
更新時間: 2月23日 週日
持股股東
股東類型
持股股東
股東統計
佔比
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
持股股東
股東統計
佔比
Federated Hermes Global Investment Management Corp.
19.40%
New Enterprise Associates (NEA)
9.76%
Vivo Capital, LLC
7.55%
Octagon Capital Advisors LP
7.32%
The Vanguard Group, Inc.
5.99%
Other
49.98%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
32.76%
Hedge Fund
27.99%
Venture Capital
17.31%
Investment Advisor
7.47%
Individual Investor
2.18%
Research Firm
0.97%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
11.13%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
137
56.09M
84.68%
-6.17M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
2022Q4
92
9.90M
62.22%
-2.24M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
12.85M
19.4%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
6.47M
9.76%
--
--
Dec 31, 2024
Vivo Capital, LLC
5.00M
7.55%
--
--
Dec 31, 2024
Octagon Capital Advisors LP
4.85M
7.32%
+585.10K
+13.72%
Dec 31, 2024
The Vanguard Group, Inc.
3.97M
5.99%
-121.67K
-2.98%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.89M
5.88%
+146.29K
+3.90%
Dec 31, 2024
Point72 Asset Management, L.P.
895.13K
1.35%
+1.37K
+0.15%
Dec 31, 2024
Deep Track Capital LP
3.26M
4.93%
--
--
Dec 31, 2024
Millennium Management LLC
2.19M
3.31%
+900.74K
+69.75%
Dec 31, 2024
Adage Capital Management, L.P.
2.00M
3.02%
--
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
公告日期
類型
比率
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1